Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why

Quick Read

Iovance Biotherapeutics (IOVA) reported Q4 revenue of $86.71M. Gross margin expanded to 50% from 38.2%.
Iovance’s internalized Philadelphia facility supports 5,000 patients annually with 32-day turnaround times.
FDA Fast Track for NSCLC addresses a market seven times larger than melanoma.
Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.^(Sponsor)

Follow 24/7 Wall St. on Google

By David Beren Published Feb 25, 1:33PM EST

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why — © SeventyFour / Shutterstock.com

A relative unknown, if you don’t watch the biotherapeutics industry, Iovance Biotherapeutics (NASDAQ:IOVA) surged 43% in the past week after reporting Q4 2025 earnings on February 24, pushing Reddit sentiment to 86 out of 100. For a stock that bottomed near $1.64 in May 2025, the turnaround is data-backed. Iovance is no longer a pipeline story. It is a commercial company with a manufacturing moat.

As far as the company’s recent numbers, Q4 revenue hit $86.71 million, up 17.7% year-over-year and roughly 30% sequentially, driven by Amtagvi, the first FDA-approved T-cell therapy for solid tumors. Gross margin reached 50% in Q4, up from 38.2% a year earlier. The per-share loss narrowed to -$0.18 from -$0.26. Full-year 2025 revenue totaled $263.5 million, a 60.6% increase within the company’s guidance range.

The Philadelphia Facility Is the Real Story

The iCTC manufacturing center in Philadelphia is really what is setting Iovance apart from other cell therapy companies that still farm out production. All lifileucel manufacturing runs through that single internalized facility, with capacity for up to 5,000 patients per year and a turnaround time of 32 days or less. COO Igor Bilinsky described it as capable of providing “uninterrupted supply and fully support anticipated global demand today and scale up for the future even during future annual maintenance periods.” That structural cost advantage is already flowing through the margin line.

Reddit Is Paying Attention

IOVA Strong 25Q4 Earnings Call
by u/supp0rtlife in wallstreetbets

One Reddit user expressed conviction in the stock, writing: “They just had a stellar Q4 earnings. CEO said there was potential for a 10-12B market cap ($60). Several catalysts still in the bag due in 26/27. Back to back to back Quarter improvement for their FDA approved product. Not selling a single share until at least $35.” This reflects one user’s personal position and is not a recommendation.

An infographic about Iovance Biotherapeutics (IOVA) presented on a dark blue background with white and light blue text and green accents. The title reads 'IOVANCE BIOTHERAPEUTICS (IOVA): COMMERCIAL BIOTECH & Q4 SENTIMENT'. Section 1, 'WHAT THE INVESTMENT IS', describes Iovance as a Commercial-Stage Biotechnology Company focused on Polyclonal Tumor Infiltrating Lymphocyte (TIL) Cell Therapies for Solid Tumors, with Amtagvi as its lead FDA-approved product, and an internalized Philadelphia Manufacturing Facility. Section 2, 'THE SOCIAL SENTIMENT SCORE', prominently displays '86' inside a green-outlined circle, with the text 'VERY BULLISH' below it, indicating the Reddit Sentiment Score for February 24-25, 2026, with moderate activity. Section 3, 'WHAT IS DRIVING THAT SCORE TODAY', lists five bullet points: Strong Q4 2025 Earnings ($86.71M, +17.7% YoY, Gross Margin ~50%), Recent Performance (stock surged 44% in past week as of Feb 24, 2026), Key Catalysts (FDA Fast Track for NSCLC offering a 7x melanoma market opportunity), Sarcoma Data (50% Confirmed ORR in early data vs. <5% standard-of-care), and Financial Runway (~$303M cash, extends to Q3 2027). Icons depict a cell attacking a tumor, a world map, a bar chart with money, and a line graph showing an upward trend. — This infographic details Iovance Biotherapeutics’ (IOVA) commercial operations, its very bullish Reddit sentiment score of 86, and the key factors driving this positive outlook following its strong Q4 2025 earnings report.

Three catalysts are driving retail interest:

Amtagvi received FDA Fast Track Designation for non-small cell lung cancer, a market roughly seven times larger than the current melanoma opportunity
Early sarcoma data showed a 50% confirmed response rate in the first six evaluable patients, against a standard-of-care response rate below 5%
Cash of approximately $303 million extends the runway into Q3 2027

As of February 25, 2026, Iovance has not yet issued formal 2026 revenue guidance, though CEO Frederick Vogt said the company expects “remarkable revenue growth in 2026” and that guidance will come soon. The analyst consensus 12-month price target sits at $10.00, compared to the current price of $3.06, with 9 of 13 analysts rated Buy or Strong Buy. NSCLC trial enrollment completion and the soft tissue sarcoma Phase 2 launch in Q2 2026 are the near-term catalysts that will determine whether momentum holds.